Circle Pharma

Circle Pharma's Therapeutic Focus

Circle Pharma is dedicated to developing macrocycle therapeutics that address 'undruggable' targets, particularly within the field of precision oncology. The company's pipeline includes a range of therapies targeting cyclin proteins, such as Cyclin A, B, D, and E. These proteins play critical roles in cell cycle regulation and are often implicated in various cancers. By focusing on these targets, Circle Pharma aims to develop effective treatments for multiple solid tumors, including small cell lung cancer (SCLC), uterine cancer, and ovarian cancer.

Circle Pharma's Innovative Approach

Circle Pharma combines structure-based rational drug design with advanced synthetic chemistry to create its unique macrocycle therapeutics. The company utilizes computational modeling to design compounds with both high target affinity and passive cell permeability. This approach allows for the rapid generation and assessment of virtual compound libraries. Their MXMOTM platform further enables the development of cell-permeable macrocycles, which are critical for targeting intracellular proteins that have been historically challenging to drug.

Circle Pharma's Research and Development

Circle Pharma's research and development efforts have yielded promising results, particularly in the area of oncology. At the 2023 AACR-NCI-EORTC International Conference, the company presented compelling data on a first-in-class Cyclin A/B inhibitor for the treatment of breast cancer. This inhibitor has shown potential not only in breast cancer but also in other cancer types where cyclin proteins are upregulated. The company's lead programs target cyclin proteins, including Cyclin A, B, D, and E, which are associated with various forms of cancer and resistance to existing therapies.

Circle Pharma's Industry Collaborations

Circle Pharma has entered into strategic collaborations to enhance its research capabilities and expand its therapeutic pipeline. Notably, the company has an agreement with Pfizer to build a screening library of macrocyclic peptides. This collaboration leverages Circle Pharma's expertise in macrocycle chemistry and Pfizer's resources, aiming to accelerate the discovery of new therapeutic candidates. Such partnerships are crucial for advancing the development of novel treatments for cancer and other diseases.

Circle Pharma's Financial Milestones

Circle Pharma has successfully raised substantial funding to support its research and development initiatives. The company secured $66 million in Series C financing and $45 million in Series B financing. These funds are instrumental in advancing the company's pipeline, expanding its research capabilities, and progressing clinical trials. The financial backing also underscores investor confidence in Circle Pharma's innovative approach to developing macrocycle therapeutics and its potential to address significant unmet medical needs in oncology.